This notion is supported by the increased levels of E-cadherin and lower levels of vimentin staining in both tongue tumors and lymph nodes observed in PXS-S1C-treated mice, and further supports the idea that LOXL2 significantly contributes to oral cancer development and that LOXL2 inhibitors may be of benefit in addressing oral cancer. Here, LOXL2 is linked to lip and oral cavity carcinoma.